| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/14/2004 | CN1466993A Recombination ªá-interferon gelatin injection |
| 01/14/2004 | CN1134539C Thrombopoietin |
| 01/14/2004 | CN1134452C Novel vitamin D receptor related polypeptides, nucleic acid sequence encoding the same and uses thereof |
| 01/14/2004 | CN1134451C Inhibitor of collagen-stimulated platelet aggregation |
| 01/14/2004 | CN1134450C LH-RH peptide analogues, their uses and pharmaceutical compositions containing them |
| 01/14/2004 | CN1134266C Methods for inducing T cell tolerance to tissue or organ graft |
| 01/14/2004 | CN1134264C Antithrombotic agents |
| 01/14/2004 | CN1134260C Method of treatment for lung diseases using antisense oligonucleotides |
| 01/13/2004 | US6677499 Modulation of memory, learning and/or anxiety states |
| 01/13/2004 | US6677445 Chimeric antisense oligonucleotides and cell transfecting formulations thereof |
| 01/13/2004 | US6677440 Isolating by anion- and/or cation-exchange chromatography at ph value below isoelectric point of protein to be isolated or combination of ion exchange chromatography with affinity chromatography and/or fractional precipitation at specified ph |
| 01/13/2004 | US6677439 Methods for isolating T. pallidum rare outer membrane proteins |
| 01/13/2004 | US6677435 Includes an active therapeutic agent joined to a blocking moiety sensitive to the catalytic action of molecules having retro- aldol and retro-michael catalytic activity; antitumor; anticarcinogenic agents |
| 01/13/2004 | US6677433 Stabilization of hypoallergenic, hyperdigestible previously reduced proteins |
| 01/13/2004 | US6677432 Osteogenic protein-1 mutant having at least one amino acid residue substitution, and having improved in vitro refolding properties in ph range of about 6.0-9.0 |
| 01/13/2004 | US6677429 Echinocandin derivatives, preparation method and application as anti-fungal agents |
| 01/13/2004 | US6677428 Cdna with nucleotide sequence 1 and protein with amino acid sequence 2 |
| 01/13/2004 | US6677367 Lysine derivative with 2-aminosulfonylthiophene substituent; acquired immunodeficiency syndrome (aids) viricides |
| 01/13/2004 | US6677359 N-substituted glycine derivatives |
| 01/13/2004 | US6677356 Concurrently administering pyridoxal-5'-phosphate, pyridoxamine, pyridoxal, or a 3-acylated pyridoxal analogue with angiotensin converting enzyme inhibitor,calcium channel blocker, adrenergic blocking agent, vasodilator or diuretic |
| 01/13/2004 | US6677352 Non-insulin dependent, latent autoimmune, gestational diabetes treatment; impaired glucose tolerance; obesity, hypotensive agents |
| 01/13/2004 | US6677338 Serotonin transport inhibitors |
| 01/13/2004 | US6677321 Methods and compositions for treatment of inflammatory disease |
| 01/13/2004 | US6677307 TGF-α polypeptides, functional fragments and methods of use therefor |
| 01/13/2004 | US6677306 Amelogenin peptides; genetic engineering |
| 01/13/2004 | US6677305 Insulin-like growth factor agonist molecules |
| 01/13/2004 | US6677304 Ophthalmic formulations |
| 01/13/2004 | US6677301 Epithelial cell proliferation stimulants; wound healing agents |
| 01/13/2004 | US6677300 Treatment of microvascular angiopathies |
| 01/13/2004 | US6677299 Method to increase cerebral blood flow in amyloid angiopathy |
| 01/13/2004 | US6677153 Antisense antibacterial method and composition |
| 01/13/2004 | US6677152 Reversal of cancer phenotype by inhibiting expression of prostate tumor inducing gene |
| 01/13/2004 | US6677145 Isolating a nucleotide sequence having specific sequence, constructing a vector consists of an isolated nucleotide sequence operably linked to a promoter, introducing the vector into host cell for expression of elongase enzyme |
| 01/13/2004 | US6677136 Glucagon antagonist domain, preferably having very little or no glucagon agonist activity, yeast-based screening phage display, rna- peptide screening, etc. attached to a vehicle, e.g., an fc domain, peg or dextran |
| 01/13/2004 | US6677135 Ret ligand (RetL) for stimulating neutral and renal growth |
| 01/13/2004 | US6677130 Mitogen-activated protein kinase p38-2 and methods of use therefor |
| 01/13/2004 | US6677126 Antibody for human translational regulator |
| 01/13/2004 | US6677117 Inducing cell differentiation |
| 01/13/2004 | US6677116 Methods for treating cancer by modulating β-catenin mediated gene expression |
| 01/13/2004 | US6676985 Bovine lactation associated immunotropic protein (CD14), encoding gene and application in B cell activation |
| 01/13/2004 | US6676949 Two-step immunization procedure against Chlamydia infection |
| 01/13/2004 | US6676948 Haemophilus adherence and penetration proteins |
| 01/13/2004 | US6676947 Use of erythropoietin for the treatment of haemochromatoses |
| 01/13/2004 | US6676946 Dendrimeric polylysine having bonded epitopes; cancer immuno-therapy |
| 01/13/2004 | US6676945 Induction immunology response |
| 01/13/2004 | US6676942 Undergoes polymerase chain reaction with primers prospa1-a4 but not prospa1-a2 |
| 01/13/2004 | US6676940 Methods and compositions for inhibiting endothelial cell and fibrinogen mediated inflammation |
| 01/13/2004 | US6676939 Methods of modulating IL-174 response |
| 01/13/2004 | US6676937 Compositions and methods for modulating vascularization |
| 01/13/2004 | US6676935 Transfection target cells; genetic engineering |
| 01/13/2004 | US6676934 Antitumor agents; prevent or suppress glucose uptake; disrupt microtubules; induce apoptosis |
| 01/13/2004 | US6676933 Synergistic mixtures; gastrointestinal disorders |
| 01/13/2004 | US6676931 Buccal, polar and non-polar spray or capsule |
| 01/13/2004 | US6676924 CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies |
| 01/13/2004 | CA2132533C Protein purification |
| 01/13/2004 | CA2000498C Osteogenic factors |
| 01/08/2004 | WO2004003567A1 Diagnostics and therapeutics for diseases associated with the g2a-receptor (g2a) |
| 01/08/2004 | WO2004003564A2 Tumour marker and the use thereof for the diagnosis and treatment of tumour diseases |
| 01/08/2004 | WO2004003561A1 Peptide rod amphiphiles and self-assembly of same |
| 01/08/2004 | WO2004003545A1 Methods and compositions for inhibition of multi-drug resistance by hyaluronan oligomers |
| 01/08/2004 | WO2004003544A1 Methods and compositions for the diagnosis and treatment of demyelinating inflammatory disorders |
| 01/08/2004 | WO2004003507A2 Methods for identifying regulators of muscle mass using amylin receptors |
| 01/08/2004 | WO2004003218A2 Antisense modulation of hypothetical protein loc51249 expression |
| 01/08/2004 | WO2004003217A1 Glutathione production |
| 01/08/2004 | WO2004003201A2 Antisense modulation of lrh1 expression |
| 01/08/2004 | WO2004003195A1 Tryptophan as a functional replacement for adp-ribose-arginine in recombinant proteins |
| 01/08/2004 | WO2004003191A1 Regulation of human map kinase kinase kinase |
| 01/08/2004 | WO2004003190A1 Polypeptide identified as a cytochrome p450 |
| 01/08/2004 | WO2004003188A2 Stabilization of granules |
| 01/08/2004 | WO2004003185A2 Plant deoxyribonucleoside kinase enzymes and their use |
| 01/08/2004 | WO2004003179A1 Differentiation modulating agents and uses therefor |
| 01/08/2004 | WO2004003176A2 Recombinant tissue protective cytokines and encoding nucleic acids thereof for protection, restoration, and enhancement of responsive cells, tissues, and organs |
| 01/08/2004 | WO2004003174A2 Method of up-regulating tumor antigen expression using thymalfasin |
| 01/08/2004 | WO2004003172A2 Esm-1 gene differentially expressed in angiogenesis, antagonists thereof, and methods of using the same |
| 01/08/2004 | WO2004003170A2 Agents capable of inhibiting ras and uses thereof |
| 01/08/2004 | WO2004003165A2 Novel polynucleotide and polypeptide sequences and uses thereof |
| 01/08/2004 | WO2004003164A2 Methods of organ regeneration |
| 01/08/2004 | WO2004003163A2 Methods and compositions for manipulating the guided navigation of endothelial tubes during angiogenesis |
| 01/08/2004 | WO2004003162A2 Enzymes |
| 01/08/2004 | WO2004003154A2 Use of streptavidin to inhibit transplant rejection |
| 01/08/2004 | WO2004003149A2 Cngh0005 polypeptides, antibodies, compositions, methods and uses |
| 01/08/2004 | WO2004003147A2 Cngh0004 polypeptides, antibodies, compositions, methods and uses |
| 01/08/2004 | WO2004003145A2 Compositions and methods for modulating physiology of epithelial junctional adhesion molecules for enhanced mucosal delivery of therapeutic compounds |
| 01/08/2004 | WO2004003140A2 Cytokine receptor zcytor17 multimers |
| 01/08/2004 | WO2004003134A2 Antisense inhibition via rnase h-independent reduction in mrna |
| 01/08/2004 | WO2004003133A1 Pain signaling molecules |
| 01/08/2004 | WO2004003121A1 Desinfecting composition |
| 01/08/2004 | WO2004003017A1 Avian cytokines, such il-12, comprising a p40 and/or p35 subunit(s) |
| 01/08/2004 | WO2004003016A2 Marked peptides having affinity for a phospholipid and uses |
| 01/08/2004 | WO2004003015A2 Peptides having affinity for a phospholipid and uses |
| 01/08/2004 | WO2004003012A2 Novel variants of the papm polypeptide of bacteria of genus streptomyces |
| 01/08/2004 | WO2004003011A2 Nuclear hormone receptor |
| 01/08/2004 | WO2004003010A2 Nuclear hormone receptor ligano-binding domain containing protein |
| 01/08/2004 | WO2004003009A2 Francisella tularensis immunogenic proteins and dna encoding these |
| 01/08/2004 | WO2004003008A2 Peptides for inducing apoptosis in tumor cells |
| 01/08/2004 | WO2004003007A1 Non-t cell binding peptides and their uses |
| 01/08/2004 | WO2004003006A2 Peptides having antimicrobial properties and compositions containing same in particular for preserving foods |
| 01/08/2004 | WO2004003005A2 Sh2 domain binding inhibitors |
| 01/08/2004 | WO2004003000A2 1’-, 2'- and 3'- modified nucleoside derivatives for treating flaviviridae infections |
| 01/08/2004 | WO2004002999A2 Modified 2' and 3' -nucleoside produgs for treating flaviridae infections |